Original title: Qianjin Pharmaceutical has no Qianjin phylloxacin, and multiple companies clarify the relationship!
Pay attention to the risk, the 15,000-fold inhibition data is only the result of in vitro experiments!
Author: Yan Cui
On May 16, the A-share Qianjintansu concept stocks rose sharply, and some of them had the daily limit for three consecutive days. The company hurriedly announced to clear the relationship, saying that there were no related products, and some companies announced that they had small product sales.
It is worth noting that Radix chinensis is a traditional Chinese medicine in my country. Fructus chinensis is an alkaloid isolated and extracted from Radix chinensis, tubers or canes of the genus Radix chinensis. It is an active ingredient of Chinese herbal medicine. It was used as an analgesic before. , Leukocyte hyperplasia drug, this patent belongs to the research progress of new use of old drugs. At present, the current research status of "Shenjintiansu" in the field of inhibiting new coronary pneumonia virus can only be called compounds under research, and clinical trials have not yet been carried out. There is still a long process to get medicine.
A report detonated concept stocks
A report detonated concept stocks
On May 16, a number of pharmaceutical companies related to fenugreek rose to the daily limit one after another.
As of the close in the afternoon, stocks such as Buchang Pharmaceutical, Fangsheng Pharmaceutical, North China Pharmaceutical, Bio Valley, Dali Pharmaceutical and other stocks have risen by the daily limit, of which 30% of Bio Valley has reached the daily limit, and other stocks such as Haoyuan Pharmaceutical, Yunnan Baiyao, and Youningwei have followed suit.
Behind the rally is a piece of news about Qianjin vines in the newspapers.
According to the "Science and Technology Daily" report on May 13, on May 10, the new drug for the treatment of new crowns discovered by Chinese scientists was authorized by the national invention patent.
The patent specification shows that 10uM (micromol/L) of fenugreek inhibits the replication of coronavirus by 15393 times.
On May 12, the patent inventor of this new drug, Professor Tong Yigang, dean of the School of Life Science and Technology, Beijing University of Chemical Technology, said in an exclusive interview with Science and Technology Daily that from the current research data, the drug's ability to inhibit the new coronavirus is in all hands. It ranks high among the novel coronavirus inhibitors discovered by human beings. Its team first discovered in February 2020 that fenugreek has super anti-coronavirus activity. The related papers published in March of the same year have now become ESI highly cited papers. It is hoped that clinical trial research can be carried out as soon as possible so that scientific and technological achievements can be implemented and practically used in the fight against the epidemic.
According to public information, Radix chinensis is a traditional Chinese medicine in my country, which belongs to the fangchi family and genus Radix chinensis.
It is an alkaloid isolated and extracted from the tubers or vines of the genus A. chinensis, and it is an active ingredient of Chinese herbal medicine. It has been approved for the treatment of various diseases.
Previously, fenugreek was mostly used for analgesics and leukocyte proliferation drugs, which can promote the proliferation of bone marrow tissue, thereby increasing white blood cells.
According to the data on the official website of the State Food and Drug Administration, from April to June 2020, Shenyang Guancheng Pharmaceutical, Yunnan Baiyao Group Wenshan Qihua, Yunnan Baiyao Group Dali Pharmaceutical, and Yunnan Bio Valley Pharmaceutical's Qianjintiansu tablets were approved for listing.
The medicine is 0.05g/tablet, and each tablet contains 20mg of fenugreek.
In addition, Nanning Baihui Pharmaceutical Co., Ltd. has a chemical drug approval document for "Qianjintanine Tablets".
However, the approved Qianjintiansu tablets are mainly used for clearing heat and cooling blood, and are used for leukopenia caused by radiotherapy in tumor patients.
The adverse reaction of this drug is occasional mild gastrointestinal discomfort. Note that it should not be taken for a long time, and it should not be taken with tea. It is forbidden for pregnant women.
In other words, fenugreek belongs to an old drug, which is used for anti-new crown research and belongs to the new use of old drugs.
On May 16, the listed company Dali Pharmaceutical had the same name as Yunnan Baiyao Dali Pharmaceutical, and opened the daily limit. Because the company name contained "Qianjin", Qianjin Pharmaceutical also had a strong daily limit.
As of May 16, the share price of Qianjin Pharmaceutical has risen by the daily limit for three consecutive days, and individual stocks such as North China Pharmaceutical, Dali Pharmaceutical, and Buchang Pharmaceutical have risen by the daily limit for two consecutive days.
Multi-Company Announcement Response
Multi-Company Announcement Response
While concept stocks skyrocketed and the concept of fenugreek became popular, many companies were asked by investors on the investor interaction platform about the actual business situation. On the evening of May 16, many companies responded positively to the relationship with fenugreek through announcements.
Qianjin Pharmaceutical’s announcement clarified that the company has no production and sales of fenugreek. The main component of the company’s main product, Fuke Qianjin tablets, is an alkaloid extracted from dried cane; The bisbenzyl isoquinoline alkaloids isolated and extracted from the vine and the genus Dianthus.
The two are not the same substance, and there are great differences in chemical structure and pharmacological effects.
Buchang Pharmaceutical announced on the evening of May 16 that the company has recently noticed that media reports listed the company as a concept stock of phyllostachys. After verification, the company's wholly-owned subsidiary Shandong Danhong Pharmaceutical Co., Ltd. (formerly Heze Buchang Pharmaceutical Co., Ltd.) With the invention patent of "a preparation method of fenugreek hydrochloride [patent number: ZL201010556531.0]", the company currently has no research and development, production and sales of fenugreek related products. Investors are advised to pay attention to investment risks.
North China Pharmaceutical announced that recently, the company noticed that some media reports mentioned that "North China Pharmaceutical and the expert team have technical cooperation related to fenugreek".
According to the company's verification, at present, the company has not carried out technical cooperation with the relevant expert team, and the company has no related products.
ST Tiansheng also replied on the investor interactive platform that the company currently does not have any products related to fenugreek.
Aladdin announced on the evening of May 16 that the total sales of the company's product "Qianjintansu" in 2021 will be 10,220.95 yuan. At present, the sales of this product have not changed significantly compared with previous years.
The scientific research reagents provided by the company are for scientific research activities, and have the characteristics of small batches and multiple specifications. The product stock is small, and the company's product specifications are mostly grams and milligrams. It is used for research and development in laboratories of scientific research institutes, not industrial raw materials.
Single product sales have little impact on the company's operating performance.
A person from the board of directors of the Bio Valley Company said that the company has the approval for the drug Qianjintiansu, but the specific production and sales data are in the relevant business departments, and the department does not have access to it.
In addition, Rhine Biotech stated on the investor interactive platform today that fenugreek belongs to alkaloids, and the company has technical reserves for the extraction of similar products.
If there is a lot of demand in the market for fenugreek in the future, the company has the confidence to quickly carry out new technology research and development and respond to market demand in a timely manner with years of experience in plant extraction and technical accumulation of similar products.
Haoyuan Medicine also recently stated that the compound fenugreek has been extracted from plants in the 1930s. Its pharmacological effects include leukocyte elevation and anti-tumor effects. Later, it was also used for leukopenia caused by radiotherapy and chemotherapy.
There is this compound in the company's product library, which is only available to scientific research customers, and the sales volume is very small. The company has noticed that this compound can inhibit the activity of coronavirus recently, and will continue to pay attention to the follow-up research progress of this compound.
Much uncertainty remains
Much uncertainty remains
It should be noted that fenugreek is not currently a patented drug.
According to industry analysts, 10uM (micromol/L) of fenugreek can inhibit the replication of coronavirus by 15,393 times. This data is only the result of in vitro experiments, and the results of in vitro experiments are still a long way from the birth of a new drug. distance.
A person in charge of an anti-viral company said that "Shenjintiansu" can only be called a compound under research at present, and animal experiments, including pharmacology, toxicology, drug metabolism and other preclinical studies, are required to complete the drug, and then I, II, Phase III clinical trials.
Meng Lilian, chief expert of Sichuan Tianfu Health Industry Research Institute, said in an interview with the media that the development of new drugs is a process of overcoming five obstacles.
According to the drug development process, this invention is still far from a new drug, and it is still unknown whether it can become a drug.
In the end, it still needs to pass the test of safety, animal testing, clinical trials and other links.
In general, all drugs that have not been approved for marketing in the preclinical or clinical laboratory stage cannot be called new drugs, but should be called drug candidates or drug candidates.
Therefore, at present, whether fenugreek can eventually become an anti-new crown drug, it also needs to go through animal tests, human clinical trials, marketing approval and other links, and there is great uncertainty whether it can pass.
In addition, it is reported that a Canadian pharmaceutical company has already approached the US FDA to conduct a clinical trial study on the treatment of new coronary pneumonia with fenugreek, and the clinical trial is expected to be officially launched in the second half of this year.
Soochow Securities pointed out that under the management and control policy of dynamic clearing, the new crown special medicine is the key to long-term prevention and control in the future.
At present, only Pfizer’s Paxlovid has been approved for listing with conditions in China, and no domestic Covid-19 medicine has been approved for marketing.
According to estimates, the cost of fenugreek is far lower than that of other drugs.
At present, the market price of Pfizer's Paxlovid is 2,300 yuan per box, and the real biological Azdof is estimated to be 900 yuan per course of treatment, while the price of the old drug, with reference to the old drug, is about 100 yuan per box.